secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001104659-25-059900
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm reports 90% of ALS patients in NurOwn EAP survived over 5 years
--------------------------------------------------------------------------

- 9 of 10 NurOwn EAP participants survived >5 years from symptom onset vs. ~10% typical survival in ALS.
- Median survival in small cohort was 6.8 years; only death was elective euthanasia.
- Company says data strengthens rationale for Phase 3b trial of NurOwn in ALS under FDA SPA.
- CEO and CMO highlighted clinically meaningful observation in press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/0001104659-25-059900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465925059900/tm2518123d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-059900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer